These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 20828791)
1. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Jansen JP; Bergman GJ; Huels J; Olson M Semin Arthritis Rheum; 2011 Feb; 40(4):275-84.e1-2. PubMed ID: 20828791 [TBL] [Abstract][Full Text] [Related]
2. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials. Deardorff WJ; Cenzer I; Nguyen B; Lee SJ JAMA Intern Med; 2022 Jan; 182(1):33-41. PubMed ID: 34807231 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis. Barrionuevo P; Kapoor E; Asi N; Alahdab F; Mohammed K; Benkhadra K; Almasri J; Farah W; Sarigianni M; Muthusamy K; Al Nofal A; Haydour Q; Wang Z; Murad MH J Clin Endocrinol Metab; 2019 May; 104(5):1623-1630. PubMed ID: 30907957 [TBL] [Abstract][Full Text] [Related]
4. [New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis]. Soen S Clin Calcium; 2009 Jan; 19(1):44-53. PubMed ID: 19122264 [TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Zhou J; Ma X; Wang T; Zhai S Osteoporos Int; 2016 Nov; 27(11):3289-3300. PubMed ID: 27273112 [TBL] [Abstract][Full Text] [Related]
6. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis. Adami S Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247 [TBL] [Abstract][Full Text] [Related]
7. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Seeman E; Boonen S; Borgström F; Vellas B; Aquino JP; Semler J; Benhamou CL; Kaufman JM; Reginster JY Bone; 2010 Apr; 46(4):1038-42. PubMed ID: 20026265 [TBL] [Abstract][Full Text] [Related]
8. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947 [TBL] [Abstract][Full Text] [Related]
9. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789 [TBL] [Abstract][Full Text] [Related]
10. Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women. Ellis AG; Reginster JY; Luo X; Bushmakin AG; Williams R; Sutradhar S; Mirkin S; Jansen JP Curr Med Res Opin; 2014 Aug; 30(8):1617-26. PubMed ID: 24773456 [TBL] [Abstract][Full Text] [Related]
11. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Reginster J-; Bianic F; Campbell R; Martin M; Williams SA; Fitzpatrick LA Osteoporos Int; 2019 Jul; 30(7):1465-1473. PubMed ID: 30953114 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials. Chen L; Wang G; Zheng F; Zhao H; Li H Osteoporos Int; 2015 Sep; 26(9):2355-63. PubMed ID: 25944731 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. Wang C Am J Ther; 2017; 24(5):e544-e552. PubMed ID: 26938765 [TBL] [Abstract][Full Text] [Related]
14. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS. Albert SG; Reddy S Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754 [TBL] [Abstract][Full Text] [Related]
15. [Role of pharmaceutical intervention in the treatment of osteoporosis and prevention of fracture]. Nakamura T Nihon Rinsho; 2009 May; 67(5):903-8. PubMed ID: 19432107 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Iwamoto J; Takeda T; Sato Y Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313 [TBL] [Abstract][Full Text] [Related]
17. [Meta-analysis of alendronate preventing hip fracture risk of postmenopausal women]. Yuan T; Li XL; Zhang CQ; Shi HP; Zeng BF Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(23):1620-2. PubMed ID: 19957509 [TBL] [Abstract][Full Text] [Related]
18. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589 [TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates for Secondary Prevention of Osteoporotic Fractures: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Shi L; Min N; Wang F; Xue QY Biomed Res Int; 2019; 2019():2594149. PubMed ID: 31828096 [TBL] [Abstract][Full Text] [Related]
20. [Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis]. Iwamoto J Clin Calcium; 2010 Mar; 20(3):396-407. PubMed ID: 20190370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]